Evidence map›Paper›PMID 35506103›Full record

ArticlePulmonary circulation2022

Clinical insights into pulmonary hypertension in chronic obstructive pulmonary disease.

Daniel P Cook, Meng Xu, Victoria L Martucci, Jeffrey S Annis, Melinda C Aldrich, Anna R Hemnes, Evan L Brittain

Open access · goldAbstract read
In one paragraph

Article in Pulmonary circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Daniel P CookDepartment of Internal Medicine Vanderbilt University Medical Center Nashville Tennessee USA.
Meng XuDepartment of Biostatistics Vanderbilt University Medical Center Nashville Tennessee USA.
Victoria L MartucciDepartment of Internal Medicine Vanderbilt University Medical Center Nashville Tennessee USA.
Jeffrey S AnnisDepartment of Vanderbilt Institute for Clinical and Translational Research Vanderbilt University Medical Center Nashville Tennessee USA.
Melinda C AldrichDepartment of Internal Medicine Vanderbilt University Medical Center Nashville Tennessee USA.
Anna R HemnesDepartment of Internal Medicine Vanderbilt University Medical Center Nashville Tennessee USA.
Evan L BrittainDepartment of Internal Medicine Vanderbilt University Medical Center Nashville Tennessee USA.
Vanderbilt University Medical Center · US

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Sex Hormones in Pulmonary Arterial HypertensionP01HL108800 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HEMNES, ANNA R · 2012 to 2021
$22.0M
Genomic and Circulating Predictors of PAH responseR01HL142720 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Anna R Hemnes · 2019 to 2026
$5.0M
Clinical, Genetic, and Proteomic Risk Factors for Pulmonary Hypertension in Heart FailureR01HL146588 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BRITTAIN, EVAN L, FREIBERG, MATTHEW S · 2019 to 2022
$3.4M
Training Program on Genetic Variation and Human PhenotypesT32GM080178 · NIGMS · VANDERBILT UNIVERSITY · PI COX, NANCY J, SAMUELS, DAVID C · 2007 to 2021
$3.1M
Mentorship in Pulmonary Vascular DiseaseK24HL155891 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Anna R Hemnes · 2022 to 2026
$573k
Unraveling the Complexities of COPD: Modeling COPD Outcomes and Phenotype Associations Using Electronic Health RecordsF30HL140756 · NHLBI · VANDERBILT UNIVERSITY · PI MARTUCCI, VICTORIA · 2018 to 2020
$109k
NCATS NIH HHS UL1 TR002243NHLBI NIH HHS F30 HL140756NHLBI NIH HHS K24 HL155891NHLBI NIH HHS P01 HL108800NHLBI NIH HHS R01 HL142720NHLBI NIH HHS R01 HL146588NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM080178
6 · The paper itself

Abstract

Pulmonary hypertension (PH) is a common complication of chronic obstructive pulmonary disease (COPD). Little is known about the prevalence and clinical profiles of patients with COPD-PH. We report the clinical characteristics, hemodynamic profiles, and prognosis in a large population of patients with COPD referred for right heart catheterization (RHC). We extracted data from all patients referred for RHC between 1997 and 2017 in Vanderbilt's deidentified medical record. PH was defined as mean pulmonary artery pressure >20 mmHg. Pre- and postcapillary PH were defined according to contemporary guidelines. COPD was identified using a validated rules-based algorithm requiring international classification of diseases codes relevant to COPD. We identified 6065 patients referred for RHC, of whom 1509 (24.9%) had COPD and 1213 had COPD and PH. Patients with COPD-PH had a higher prevalence of diabetes, atrial fibrillation, and heart failure compared with COPD without PH. Approximately 55% of patients with COPD-PH had elevated left ventricle (LV) filling pressure. Pulmonary function testing data from individuals with COPD-PH revealed subtype differences, with precapillary COPD-PH having lower diffusion capacity of the lungs for carbon monoxide (DLCO) values than the other COPD-PH subtypes. Patients with COPD-PH had significantly increased mortality compared with COPD alone (hazard ratio [HR]: 1.70, 95% confidence interval [CI]: 1.28-2.26) with the highest mortality among the combined pre- and postcapillary COPD-PH subgroup (HR: 2.39; 95% CI: 1.64-3.47). PH is common among patients with COPD referred for RHC. The etiology of PH in patients with COPD is often mixed due to multimorbidity and is associated with high mortality, which may have implications for risk factor management.

Indexed as

COPDhemodynamic phenotypingsurvival outcomes

Identifiers

PMID35506103
PMCPMC9052979
OpenAlexW4206019693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.